Trial testing whether genomic test results can help guide decisions between active surveillance and treatment for people with favourable intermediate-risk prostate cancer that has not spread beyond the prostate. Participants will be randomly assigned to undertake genomic testing or not, before commencing active surveillance.
Inclusion Criteria
1. Age 18 years and over.
2. Histological diagnosis of prostate adenocarcinoma with no evidence of metastatic disease on staging investigations (if indicated).
3. Intermediate risk prostate cancer as defined clinical stage cT2 OR Gleason Sum 3+4 = 7 (International Society of Urological Pathology (ISUP) grade group 2) OR Prostate-specific antigen test (PSA) 10-20 ng/mL.
4. Fit for radical treatment (either surgery or radiation) at the time of diagnosis.
5. Estimated life expectancy > 10 years.
6. Availability of formalin-fixed, paraffin-embedded tissue cores for genomic testing.
Exclusion Criteria
1. Unwilling to accept active surveillance as an initial management strategy.
2. The presence of any variant prostate cancer histology (ductal, small cell, sarcomatoid, urothelial, squamous/adenosquamous carcinoma and basal cell carcinoma).
3. The presence of high-risk pattern 4 growth patterns (in the pattern 4 component of Gleason 3+4 disease), namely intraductal carcinoma or large cribriform pattern.
4. Unable or unwilling to provide informed consent.
*Trial is being conducting at the Princess Alexandra Hospital
Contact Prof Samantha Oakes +61 02 9054 3600 Email trials@anzup.org.au
